Morgan Stanley Raises its Price Target on Recursion (RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 10 Best Penny Stocks to Buy for Long Term.

On May 14, 2026, Morgan Stanley raised the firm’s price target on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) to $5.50 from $5 and kept an Equal Weight rating on the shares.

On May 6, 2026, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported Q1 EPS of (22c), versus the consensus estimate of (26c). Revenue totaled $6.47M, versus the consensus estimate of $15.78M. Cash, cash equivalents, and restricted cash stood at $665.2M, compared to $753.9M as of December 31, 2025. The company continues to expect its cash runway to extend into early 2028. CEO and President Najat Khan said the company is seeing strong momentum and execution across its portfolio, with increasing evidence that its integrated platform can translate biological and chemical insights into differentiated clinical programs. Khan added that recent developments, including initial safety and pharmacokinetic data from REC-1245 and the dosing of the first patient in REC-4539, represent additional proof points supporting the company’s end-to-end AI-driven drug discovery platform.

Morgan Stanley Raises its Price Target on Recursion (RXRX)

Last month, JPMorgan lowered the firm’s price target on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) to $10 from $11 previously and kept an Overweight rating on the shares.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company focused on using AI, automation, and data science to industrialize drug discovery.

While we acknowledge the risk and potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RXRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1